Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Anne Camez"'
Autor:
Andrew Blauvelt, Melinda Gooderham, Ziqian Geng, Atsuyuki Igarashi, Jashin J. Wu, David A. Williams, Richard G. Langley, Tianshuang Wu, Anne Camez, Kim A. Papp, Mary Flack, Sandra Philipp, Craig L. Leonardi
Publikováno v:
JAMA dermatology. 156(6)
Risankizumab selectively inhibits interleukin 23, a cytokine that contributes to psoriatic inflammation.To evaluate the efficacy and safety of risankizumab vs placebo and continuous treatment vs withdrawal in adults with moderate to severe plaque pso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27e608bf3bbf7e9f1e518095b658c533
https://pubmed.ncbi.nlm.nih.gov/32267471
https://pubmed.ncbi.nlm.nih.gov/32267471
Autor:
Alexandra P. Song, Nobuhisa Mizuki, Anne Camez, Antoine P. Brézin, Nisha V. Kwatra, Masanori Miyazaki, Noritaka Inomata, Andrew D. Dick, Quan Dong Nguyen, Noriyasu Hashida, Toshikatsu Kaburaki, Martina Kron, Masahiro Zako, Glenn J. Jaffe, Koju Kamoi, Hiroshi Goto, Samir R. Tari, Koh Hei Sonoda, Toshiaki Abe, Shigeaki Ohno, Kenichi Namba
Publikováno v:
Goto, H, Zako, M, Namba, K, Hashida, N, Kaburaki, T, Miyazaki, M, Sonoda, K H, Abe, T, Mizuki, N, Kamoi, K, Brézin, A P, Dick, A D, Jaffe, G J, Nguyen, Q D, Inomata, N, Kwatra, N V, Camez, A, Song, A P, Kron, M, Tari, S & Ohno, S 2018, ' Adalimumab in Active and Inactive, Non-Infectious Uveitis : Global Results from the VISUAL I and VISUAL II Trials ', Ocular Immunology and Inflammation . https://doi.org/10.1080/09273948.2018.1491605
PURPOSE: Report global adalimumab safety and efficacy outcomes in patients with non-infectious uveitis.METHODS: Adults with non-infectious intermediate, posterior, or panuveitis were randomized 1:1 to receive placebo or adalimumab in the VISUAL I (ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57a12c9d9b4c8176e6ed9def9ce50501
https://doi.org/10.1080/09273948.2018.1491605
https://doi.org/10.1080/09273948.2018.1491605
Autor:
Yanjun Bao, Anne Camez, Avani Joshi, Manish Mittal, Samir R. Tari, Keith A. Betts, Jennifer E. Thorne, Eric B. Suhler
Publikováno v:
Ophthalmology. 124:1799-1807
Purpose Chronic use of corticosteroids for the treatment of uveitis has been linked with drug-associated toxicity and adverse events (AEs). This study examines the association between corticosteroid dosage and incidence rates of corticosteroid-relate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b07d37050726d7eb8c75d6ee9afffd7f
https://doi.org/10.1016/j.ophtha.2017.06.017
https://doi.org/10.1016/j.ophtha.2017.06.017
Publikováno v:
Clinical pharmacokinetics. 58(6)
The objective of this study was to characterize the effects of risankizumab on the in vivo activity of cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A in psoriasis patients using a cocktail approach. Patients with moderate to severe chr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::792ba164afc36ec5a91e899fdb84366f
https://pubmed.ncbi.nlm.nih.gov/30574672
https://pubmed.ncbi.nlm.nih.gov/30574672
Autor:
Sophia Pathai, Jianzhong Liu, Glenn J. Jaffe, Martina Kron, Toshikatsu Kaburaki, Samir R. Tari, Alfredo Adán, Luca Cimino, Joachim Van Calster, Lyndell L Lim, Alexandra P. Song, Quan Dong Nguyen, Eric Fortin, Manfred Zierhut, Ariel Schlaen, Andrew D. Dick, Anne Camez, Antoine P. Brézin, Eric B. Suhler, Mirjam E.J. van Velthoven, Albert T. Vitale, Michal Kramer, Cristina Muccioli, Hiroshi Goto
Publikováno v:
Suhler, E B, Adán, A, Brézin, A P, Fortin, E, Goto, H, Jaffe, G J, Kaburaki, T, Kramer, M, Lim, L L, Muccioli, C, Nguyen, Q D, Van Calster, J, Cimino, L, Kron, M, Song, A P, Liu, J, Pathai, S, Camez, A, Schlaen, A, van Velthoven, M E J, Vitale, A T, Zierhut, M, Tari, S & Dick, A D 2018, ' Safety and Efficacy of Adalimumab in Patients with Noninfectious Uveitis in an Ongoing Open-Label Study : VISUAL III ', Ophthalmology, vol. 125, no. 7, pp. 1075-1087 . https://doi.org/10.1016/j.ophtha.2017.12.039
PURPOSE: To evaluate safety and efficacy of adalimumab in patients with noninfectious intermediate, posterior, or panuveitis. DESIGN: Phase 3, open-label, multicenter clinical trial extension (VISUAL III). PARTICIPANTS: Adults meeting treatment failu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd8f86f1a04d653528b0eaa4bbca8c47
https://pubmed.ncbi.nlm.nih.gov/29429764
https://pubmed.ncbi.nlm.nih.gov/29429764
Autor:
Eric B, Suhler, Jennifer E, Thorne, Manish, Mittal, Keith A, Betts, Samir, Tari, Anne, Camez, Yanjun, Bao, Avani, Joshi
Publikováno v:
Ophthalmology. 124(12)
Chronic use of corticosteroids for the treatment of uveitis has been linked with drug-associated toxicity and adverse events (AEs). This study examines the association between corticosteroid dosage and incidence rates of corticosteroid-related AEs.A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5903ada74137708f5c68123031f8c5db
https://pubmed.ncbi.nlm.nih.gov/28689898
https://pubmed.ncbi.nlm.nih.gov/28689898
Autor:
Andrew D. Dick, Glenn J. Jaffe, David Scales, Philippe Kestelyn, Arnd Heiligenhaus, Talin Barisani-Asenbauer, Nisha V. Kwatra, Quan Dong Nguyen, Pablo Franco, Anne Camez, Antoine P. Brézin, David S Chu, Martina Kron, Eric B. Suhler, Alexandra P. Song, Samir R. Tari, Jennifer E. Thorne
Publikováno v:
Jaffe, G J, Dick, A D, Brézin, A P, Nguyen, Q D, Thorne, J E, Kestelyn, P, Barisani-Asenbauer, T, Franco, P, Heiligenhaus, A, Scales, D, Chu, D S, Camez, A, Kwatra, N V, Song, A P, Kron, M, Tari, S & Suhler, E B 2016, ' Adalimumab in Patients with Active Noninfectious Uveitis ', New England Journal of Medicine, vol. 375, no. 10, pp. 932-943 . https://doi.org/10.1056/NEJMoa1509852
Background Patients with noninfectious uveitis are at risk for long-term complications of uncontrolled inflammation, as well as for the adverse effects of long-term glucocorticoid therapy. We conducted a trial to assess the efficacy and safety of ada
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e0fba15c3e57771eb243f0e558c6fd0
https://research-information.bris.ac.uk/en/publications/f3a8b851-dde7-47cf-b5df-aa714b87eb05
https://research-information.bris.ac.uk/en/publications/f3a8b851-dde7-47cf-b5df-aa714b87eb05
Autor:
Anne Camez, Samir R. Tari, Antoine P. Brézin, Shree Kurup, Luca Cimino, Quan Dong Nguyen, Ariel Schlaen, Carlos Pavesio, Glenn J. Jaffe, Nisha V. Kwatra, John D. Sheppard, Alexandra P. Song, Joachim Van Calster, Pauline T. Merrill, Martina Kron, Andrew D. Dick
Publikováno v:
Nguyen, Q D, Merrill, P T, Jaffe, G J, Dick, A D, Kurup, S K, Sheppard, J, Schlaen, A, Pavesio, C, Cimino, L, Van Calster, J, Camez, A A, Kwatra, N V, Song, A P, Kron, M, Tari, S & Brézin, A P 2016, ' Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II) : a multicentre, double-masked, randomised, placebo-controlled phase 3 trial ', Lancet, vol. 388, no. 10050, pp. 1183-1192 . https://doi.org/10.1016/S0140-6736(16)31339-3
BackgroundNon-infectious uveitis is a potentially sight-threatening ocular disorder caused by chronic inflammation and its complications. Therapeutic success is limited by systemic adverse effects associated with long-term corticosteroid and immunomo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa636421c21bde5ca36a7eef02cfe326
https://hdl.handle.net/11380/1259080
https://hdl.handle.net/11380/1259080
Autor:
Mamoru, Watanabe, Toshifumi, Hibi, Kathleen G, Lomax, Susan K, Paulson, Jingdong, Chao, M Shamsul, Alam, Anne, Camez, K, Okawa
Publikováno v:
Journal of Crohn's and Colitis. 6:160-173
Background and aims Adalimumab has been shown to be efficacious and well-tolerated in Western patients with Crohn's disease. These 2 randomized, double-blind clinical trials evaluated adalimumab efficacy and safety in Japanese patients with moderate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f90de04f9a7e27c58ce8e31c5e55960
https://doi.org/10.1016/j.crohns.2011.07.013
https://doi.org/10.1016/j.crohns.2011.07.013
Autor:
Robert Löfberg, Walter Reinisch, Anne M. Robinson, Anne Camez, Paul F. Pollack, Martina Kron, Edouard Louis
Publikováno v:
Inflammatory Bowel Diseases. 18:1-9
Background: Data regarding the effectiveness of anti-tumor necrosis factor (TNF) agents for resolution of extraintestinal manifestations (EIMs) are scarce. The CARE study evaluated clinical effectiveness, EIM resolution, and safety of adalimumab in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0affb7235d1bc51514a5aa6a86b539de
https://doi.org/10.1002/ibd.21663
https://doi.org/10.1002/ibd.21663